03366nam a2200409 a 4500001001400000003000700014005001700021006001900038007001500057008004100072020001800113020001500131020003500146020003200181020001800213020001500231040000800246245028700254260005700541300006500598500005900663504004000722505059000762516003101352520094201383538003002325650005302355650005702408650005602465650006602521650002202587650003902609650004202648650004202690710011202732856011202844vtls000051048KUKTEM20251117141416.0m    f   d        cr mnu---uuuuu110110t2009    dcua   fob    000 0 eng d  a9780309130394  a0309130395  a9780309130400 (electronic bk.)  a0309130409 (electronic bk.)  a9786612239243  a6612239247  aUMP00aMedical isotope production without highly enriched uraniumh[electronic resource] /cCommittee on Medical Isotope Production Without Highly Enriched Uranium, Nuclear and Radiation Studies Board, Division of Earth and Life Studies, National Research Council of the National Academies  aWashington, D.C. :bNational Academies Press,cc2009  a1 electronic text (xviii, 202 p.) :bdigital, GIF, PDF, ill.  aTitle from electronic title page (viewed June 1, 2009)  aIncludes bibliographical references0 aBackground and study task -- Molybdenum-99/Technetium-99m production and use -- Molybdenum-99/Technetium-99m supply -- Molybdenum-99/Technetium-99m supply reliability -- Molybdenum-99/Technetium-99m demand -- Molybdenum-99/Technetium-99m production costs -- Conversion to LEU-based production of Molybdenum-99: technical considerations -- Conversion to LEU-based production of Molybdenum-99: regulatory considerations -- Conversion to LEU-based production of Molybdenum-99: general approaches and timing -- Conversion to LEU-based production of Molybdenum-99: prospects and feasibility  aText in GIF and PDF format  a"This book is the product of a congressionally mandated study to examine the feasibility of eliminating the use of highly enriched uranium (HEU2) in reactor fuel, reactor targets, and medical isotope production facilities. The book focuses primarily on the use of HEU for the production of the medical isotope molybdenum-99 (Mo-99), whose decay product, technetium-99m3 (Tc-99m), is used in the majority of medical diagnostic imaging procedures in the United States, and secondarily on the use of HEU for research and test reactor fuel.  The supply of Mo-99 in the U.S. is likely to be unreliable until newer production sources come online. The reliability of the current supply system is an important medical isotope concern; this book concludes that achieving a cost difference of less than 10 percent in facilities that will need to convert from HEU- to LEU-based Mo-99 production is much less important than is reliability of supply"  aMode of access : Internet 0aMolybdenumxSupply & distributionzUnited States 0aMolybedenumxIsolation & purificationzUnited States 0aRadioisotopesxsupply & distributionzUnited States 0aTechnetium Compoundsxisolation & purificationzUnited States 0aUraniumxIsotopes 0aUraniumxIsotopesxTherapeutic use 0aMolybdenumxIsotopesxTherapeutic use 0aTechnetiumxIsotopesxTherapeutic use2 aNational Research Council (U.S.).bCommittee on Medical Isotope Production Without Highlty Enriched Uranium403NetLibraryuhttp://www.netlibrary.com.libraryumpsa.idm.oclc.org/urlapi.asp?action=summary&v=1&bookid=285289